Defining the mechanisms of action of drug candidates that can reactivate latent proviruses presents formidable challenges both because studies ofthe physiological mechanisms responsible for proviral reactivation are incomplete and because there are no universally accepted primary cell models for HIV and SIV latency that can be used to support the development of new drugs. This project has been designed to address these critical Collaboratory strategic needs by defining how the sequential activation of multiple signaling pathways modifies the duration and magnitude ofthe HIV transcriptional response in primary cell models for HIV latency and by defining the role of the accessory protein Nef in establishing and maintaining HIV and SIV latency. We hypothesize that sustained HIV proviral reactivation minimally requires both the activation of P-TEFb and the sequential activation of NF-Kappa B, NFAT and AP-1. As part of our further development ofthe primary cell model we have recently made the surprising and discovery that proviral silencing is strongly enhanced in cells infected with viruses expressing Nef. We hypothesize that disruption of cell signaling pathways by Nef creates an environment that promotes viral entry into latency. Since Nef has long been known to enhance viral replication and spread, the obsen/ation that Nef also increases the frequency of HIV silencing raises the intriguing possibility that proviral latency is an important mechanism used to disseminate viruses eariy during infections and to escape the strong immune responses mounted during acute infections. In the course of these studies we will be interacting closely with other Collaboratory investigators. Key interactions will include the detailed evaluation of candidate drugs in our pipeline (Hazuda), development of latency models in primary cells (Planelles), development of latency models for SIV (Clements), and evaluation of new cellijlar factors that contribute to the maintenance of HIV latency (Greene, Verdin, Ofi and Peteriin).

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI096113-03
Application #
8497425
Study Section
Special Emphasis Panel (ZAI1-JBS-A)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$312,503
Indirect Cost
$23,256
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Showing the most recent 10 out of 221 publications